Narasimhan's Culture Club On Song At Novartis
Executive Summary
Taking over at the Swiss firm as CEO in 2018, Vas Narasimhan set about creating an "inspired, curious and unbossed organization." Two years on, he has put the spotlight on several initiatives that are up and running on a number of fronts to achieve that goal.
You may also be interested in...
PROFILE: Vas Narasimhan on many Novartis roles, extinction fears and Hilleman influences
Dr Vas Narasimhan, a self-proclaimed history geek, is the current head of global development for Novartis Pharmaceuticals but he still considers himself a physician first when it comes to decision making.
Finance Watch: Up, Up And Away – Biopharma Stocks Keep Rising
Public Company Edition: Drug developers continue to take advantage of investors’ preference for biotechnology investments, with CRISPR, Acceleron and BioNTech raising massive sums. The wealth isn’t spreading to everyone, however, as DBV Technologies is restructuring and cutting jobs.
Triple Joy For European Biotechs As FDA OKs Byfavo
Having secured FDA approval, the UK's Acacia Pharma will market Byfavo, the first new product in the sedation space in decades, which was licensed from Italy's Cosmo and developed by Germany's Paion.
Need a specific report? 1000+ reports available
Buy Reports